Filing Overview
Registrant: Eliem Therapeutics, Inc. The submitted metadata identifies Climb Bio, Inc., but the filing names Eliem Therapeutics, Inc. as the registrant. This Form 8-K was filed April 25, 2022 under Item 8.01, “Other Items.” No financial reporting period or financial statements are included.
Key Clinical and Business Updates
- ETX-810 in diabetic peripheral neuropathic pain: A Phase 2a trial in 159 subjects did not achieve statistically significant separation from placebo on the primary endpoint, change from baseline to Week 4 in weekly average daily pain score.
- The trial included 78 subjects receiving 1,000 mg of ETX-810 twice daily and 81 receiving placebo. ETX-810 was reported to be well tolerated, with an encouraging safety profile.
- Eliem does not currently plan to further develop ETX-810 for diabetic peripheral neuropathic pain.
- ETX-810 in lumbosacral radiculoplexus pain: The Phase 2a proof-of-concept trial was fully enrolled with 149 patients. Topline data were expected in the third quarter of 2022.
- ETX-155: The Phase 1b photosensitive epilepsy study remained ongoing. Interim results from three evaluated patients were inconclusive regarding the photoparoxysmal response.
- Drug exposures in the Phase 1b study were significantly lower than expected based on two prior Phase 1 studies in healthy subjects. The company was investigating potential causes, including differences between drug-product lots.
- Eliem delayed enrollment in planned Phase 2a trials of ETX-155 for major depressive disorder and perimenopausal depression and stated that it would update timelines after completing its investigation.
- The FDA had cleared Eliem’s IND application to proceed with Phase 2a development of ETX-155 in depression.
Financial Metrics and Liquidity
This filing does not provide revenue, profit or loss, cash flow, margins, debt, cash balances, liquidity measures, or other financial metrics. It does not contain quantitative guidance regarding financial performance or capital requirements.
Material Changes Versus the Prior Comparable Period
- ETX-810 failed its primary efficacy endpoint in diabetic peripheral neuropathic pain, resulting in a decision not to pursue further development for that indication.
- ETX-155 depression-program enrollment was delayed after inconclusive interim epilepsy-study results and unexpectedly low drug exposure levels.
- The ETX-810 lumbosacral radiculoplexus pain study reached full enrollment, with data expected in the third quarter of 2022.
Outlook, Risks, and Unusual Items
Management’s forward-looking statements depend on clinical efficacy and safety, trial execution, data availability, regulatory approvals, intellectual property protection, capital sufficiency, development costs, competition, economic conditions, and potential effects of pandemics including COVID-19. The principal unusual items are the failed ETX-810 endpoint, the discontinuation decision for diabetic peripheral neuropathic pain, inconclusive ETX-155 interim findings, and unexpectedly low ETX-155 exposure in the Phase 1b study.
Investor Verification Checklist
- Verify the registrant identity, because the filing names Eliem Therapeutics, Inc., while the request metadata names Climb Bio, Inc.
- Review subsequent filings for the ETX-810 lumbosacral radiculoplexus pain topline results and any resulting development decision.
- Confirm the root cause and resolution of the low ETX-155 drug exposure and whether Phase 2a depression trials resumed.
- Review the company’s latest periodic filings for cash runway, liquidity, operating losses, financing needs, and development spending, none of which are provided in this Form 8-K.
- Assess the implications of discontinuing ETX-810 development in diabetic peripheral neuropathic pain for the company’s broader pipeline and valuation.